Y-mAbs Therapeutics IncNASDAQ:YMAB
- LAST PRICE12.1000
- TODAY'S CHANGE (%)0.0900 (0.7494%)
- Bid / Lots10.4400/ 1
- Ask / Lots16.2100/ 2
- Open / Previous Close12.0100 / 12.0100
- Day Range
- 52 Week Range
- Volume902,462
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | YMAB |
|---|---|---|
| 09:32 ET | 1142 | 12.01 |
| 09:38 ET | 300 | 12.28 |
| 09:39 ET | 200 | 12.17 |
| 09:41 ET | 100 | 12.17 |
| 09:45 ET | 2093 | 12.215 |
| 09:48 ET | 1500 | 12.15 |
| 09:50 ET | 1731 | 12.15 |
| 09:52 ET | 4485 | 12.23 |
| 09:54 ET | 230 | 12.22 |
| 09:56 ET | 2720 | 12.34 |
| 09:57 ET | 400 | 12.3 |
| 09:59 ET | 200 | 12.26 |
| 10:01 ET | 654 | 12.34 |
| 10:03 ET | 100 | 12.34 |
| 10:08 ET | 2203 | 12.41 |
| 10:14 ET | 1018 | 12.39 |
| 10:15 ET | 100 | 12.34 |
| 10:17 ET | 1270 | 12.33 |
| 10:21 ET | 200 | 12.315 |
| 10:24 ET | 200 | 12.325 |
| 10:26 ET | 5199 | 12.19 |
| 10:28 ET | 1100 | 12.16 |
| 10:30 ET | 292 | 12.161 |
| 10:32 ET | 179 | 12.161 |
| 10:35 ET | 326 | 12.195 |
| 10:39 ET | 2210 | 12.27 |
| 10:42 ET | 100 | 12.28 |
| 10:44 ET | 100 | 12.28 |
| 10:46 ET | 100 | 12.28 |
| 10:48 ET | 100 | 12.27 |
| 10:51 ET | 100 | 12.27 |
| 10:53 ET | 100 | 12.28 |
| 10:55 ET | 200 | 12.22 |
| 10:57 ET | 100 | 12.27 |
| 11:00 ET | 3501 | 12.18 |
| 11:02 ET | 653 | 12.16 |
| 11:04 ET | 1032 | 12.15 |
| 11:06 ET | 300 | 12.15 |
| 11:08 ET | 1731 | 12.17 |
| 11:09 ET | 100 | 12.16 |
| 11:11 ET | 1254 | 12.18 |
| 11:13 ET | 100 | 12.2 |
| 11:15 ET | 1250 | 12.17 |
| 11:18 ET | 10569 | 12 |
| 11:20 ET | 613 | 11.99 |
| 11:22 ET | 3884 | 12.04 |
| 11:24 ET | 100 | 12.03 |
| 11:26 ET | 433 | 12.05 |
| 11:27 ET | 1309 | 12.045 |
| 11:29 ET | 600 | 12.07 |
| 11:31 ET | 400 | 12.12 |
| 11:36 ET | 200 | 12.11 |
| 11:38 ET | 200 | 12.085 |
| 11:40 ET | 100 | 12.11 |
| 11:42 ET | 100 | 12.085 |
| 11:44 ET | 300 | 12.085 |
| 11:45 ET | 100 | 12.11 |
| 11:49 ET | 400 | 12.11 |
| 11:51 ET | 100 | 12.11 |
| 11:56 ET | 200 | 12.11 |
| 11:58 ET | 100 | 12.11 |
| 12:00 ET | 2297 | 12.065 |
| 12:02 ET | 1100 | 11.99 |
| 12:07 ET | 100 | 11.965 |
| 12:14 ET | 800 | 11.94 |
| 12:16 ET | 1124 | 11.99 |
| 12:18 ET | 100 | 11.97 |
| 12:21 ET | 800 | 11.94 |
| 12:23 ET | 200 | 11.9552 |
| 12:25 ET | 150 | 11.94 |
| 12:27 ET | 200 | 11.92 |
| 12:30 ET | 3675 | 11.98 |
| 12:34 ET | 300 | 11.97 |
| 12:36 ET | 631 | 11.975 |
| 12:39 ET | 500 | 11.99 |
| 12:43 ET | 100 | 12 |
| 12:48 ET | 700 | 12.025 |
| 12:50 ET | 100 | 12.04 |
| 12:52 ET | 100 | 12.025 |
| 12:54 ET | 100 | 12.04 |
| 12:57 ET | 600 | 12.025 |
| 01:01 ET | 700 | 12.06 |
| 01:03 ET | 100 | 12.08 |
| 01:06 ET | 100 | 12.09 |
| 01:08 ET | 246 | 12.07 |
| 01:10 ET | 100 | 12.08 |
| 01:12 ET | 100 | 12.08 |
| 01:14 ET | 225 | 12.055 |
| 01:15 ET | 100 | 12.08 |
| 01:17 ET | 2253 | 12.05 |
| 01:19 ET | 1213 | 12.14 |
| 01:21 ET | 100 | 12.14 |
| 01:28 ET | 1378 | 12.1 |
| 01:30 ET | 3679 | 12.03 |
| 01:32 ET | 300 | 12.02 |
| 01:33 ET | 400 | 11.99 |
| 01:35 ET | 2707 | 12.03 |
| 01:42 ET | 2034 | 12.02 |
| 01:44 ET | 500 | 12.01 |
| 01:46 ET | 100 | 12.015 |
| 01:48 ET | 100 | 12.015 |
| 01:50 ET | 450 | 12.005 |
| 01:51 ET | 1100 | 12.02 |
| 01:53 ET | 3526 | 12.005 |
| 01:55 ET | 4831 | 12 |
| 01:57 ET | 619 | 12 |
| 02:00 ET | 8756 | 12.04 |
| 02:02 ET | 300 | 12.03 |
| 02:06 ET | 100 | 12.03 |
| 02:08 ET | 2379 | 12.05 |
| 02:09 ET | 1615 | 12.06 |
| 02:11 ET | 2226 | 12.03 |
| 02:15 ET | 254 | 12.04 |
| 02:22 ET | 1200 | 12.05 |
| 02:24 ET | 200 | 12.045 |
| 02:26 ET | 1641 | 12.1 |
| 02:27 ET | 500 | 12.08 |
| 02:29 ET | 1600 | 12.06 |
| 02:31 ET | 796 | 12.02 |
| 02:33 ET | 100 | 12.03 |
| 02:38 ET | 100 | 12.03 |
| 02:40 ET | 700 | 12.01 |
| 02:42 ET | 2406 | 12.02 |
| 02:49 ET | 3829 | 12.01 |
| 02:54 ET | 971 | 12 |
| 02:56 ET | 1528 | 12.01 |
| 02:58 ET | 200 | 12.01 |
| 03:00 ET | 1300 | 12.005 |
| 03:02 ET | 1611 | 12 |
| 03:03 ET | 4803 | 12.025 |
| 03:05 ET | 200 | 12.02 |
| 03:07 ET | 550 | 12.02 |
| 03:09 ET | 100 | 12.02 |
| 03:12 ET | 300 | 12.01 |
| 03:14 ET | 4144 | 12 |
| 03:16 ET | 1626 | 12 |
| 03:18 ET | 525 | 12 |
| 03:20 ET | 600 | 12 |
| 03:21 ET | 15843 | 11.97 |
| 03:23 ET | 2256 | 11.995 |
| 03:25 ET | 200 | 12 |
| 03:27 ET | 1238 | 12.01 |
| 03:30 ET | 1663 | 11.99 |
| 03:32 ET | 100 | 11.9912 |
| 03:34 ET | 1247 | 12.005 |
| 03:36 ET | 3403 | 12.01 |
| 03:38 ET | 1781 | 12 |
| 03:39 ET | 1691 | 12.01 |
| 03:41 ET | 6621 | 11.94 |
| 03:43 ET | 3651 | 11.97 |
| 03:45 ET | 2470 | 11.98 |
| 03:48 ET | 3550 | 12 |
| 03:50 ET | 4122 | 12.02 |
| 03:52 ET | 6385 | 12.14 |
| 03:54 ET | 2100 | 12.135 |
| 03:56 ET | 10461 | 12.12 |
| 03:57 ET | 5621 | 12.07 |
| 03:59 ET | 471095 | 12.1 |
Today
May 8, 2024
DJ Y-mAbs Therapeutics Down Over 17%, on Pace for Largest Percent Decrease Since October 2022 -- Data Talk, from 1:15PM ET on Wednesday May 08, 2024 by Dow Jones
1:15PM ET on Wednesday May 08, 2024 by Dow Jones
May 7, 2024
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments, from 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
4:05PM ET on Tuesday May 07, 2024 by Dow Jones*DJ Y-mAbs Therapeutics 1Q Loss/Shr 15c >YMAB, from 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
4:05PM ET on Tuesday May 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Y-mAbs Therapeutics Inc | 531.0M | -24.4x | --- |
Urogen Pharma Ltd | 480.5M | -3.9x | --- |
Zymeworks Inc | 599.6M | -4.7x | --- |
Alector Inc | 474.2M | -3.5x | --- |
Editas Medicine Inc | 427.6M | -2.5x | --- |
SAGE Therapeutics Inc | 668.6M | -1.3x | --- |
Company Information
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Contact Information
- Headquarters
- 230 PARK AVENUE, SUITE 3350NEW YORK, NY, United States 10169
- Phone
- 212-847-9841
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- James Healy
- President, Chief Executive Officer, Director
- Michael Rossi
- Vice Chairman of the Board, Chief Business Officer
- Thomas Gad
- Chief Financial Officer, Executive Vice President, Treasurer, Secretary
- Bo Kruse
- Chief Operating Officer, Senior Vice President
- Joris Wilms
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $531.0M |
|---|---|
Revenue (TTM) | $84.5M |
Shares Outstanding | 43.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.69 |
EPS | $-0.50 |
Book Value | $2.31 |
P/E Ratio | -24.4x |
Price/Sales (TTM) | 6.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -29.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
